NAFLD Summit 2022


15-17 September Dublin
N. Poster
Poster title
Applicant name
  P05-001 Impact of resmetirom-mediated reductions in liver volume and steatosis compared with placebo on the quantification of fibrosis using second harmonic generation in a serial liver biopsy study Stephen Harrison Received Received
  P03-001 Retrospective artificial intelligence-based measurement of NASH histology (AIM-NASH) analysis of biopsies from phase 2 study of resmetirom confirms significant treatment-induced changes in histologic features of nonalcoholic steatohepatitis Stephen Harrison Received Received
  P04-001 Biomarkers, imaging, and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor-beta ive agonist, for 52 weeks Stephen Harrison Received Received
  P01-001 Single-nucleotide polymorphisms in the DNA repair genes affect the risk of nonalcoholic fatty liver disease occurrence Sylwia Ziólkowska Received Received
  P02-001 Non-alcoholic fatty liver disease and sarcopenic obesity Kateryna Pivtorak Received Received
  P06-001 High yield of systematic hepatitis B virus screening among migrants in Amsterdam, the Netherlands with increased risk for non-alcoholic fatty liver disease Anne-Marieke Van Dijk Received Received
  P01-002 Pulse wave velocity is correlated with decline in renal filtration rate in non-alcoholic fatty liver disease patients Said TAHARBOUCHT Received Received
  P06-002 Pancreatic T1 values on magnetic resonance imaging are correlated with portal inflammation scores on liver biopsy in patients with non-alcoholic fatty liver disease Anne Linde Mak Received Received
  P05-002 Impact of bariatric surgery, gender, vitality and depressive symptoms on self-perceived health of obese patients with non-alcoholic fatty liver disease Jesús Funuyet-Salas Received Received
  P02-002 Simple anthropometrics may improve non-invasive tests for the prediction of fibrosis in an elderly population: the Rotterdam study Laurens van Kleef Received Received
  P03-002 Utility of FIB-4 thresholds to identify patients with at-risk F2-F3 nonalcoholic steatohepatitis based on screening data from a 2000 patient biopsy-confirmed cohort of resmetirom phase 3 trial (MAESTRO-NASH) Jrn Schattenberg Received Received
  P07-002 Metabolic syndrome correlates to a higher risk of fibrosis by surrogate scores compared to patients who do not fully meet the syndrome diagnostic criteria Valentino Osti Received Received
  P04-002 Multi-omic machine learning panel accurately stage fibrosis in asian patients with NAFLD: a prospective derivation and validation study Jin Chai Received Received
  P07-003 The effects of a structured dietetic intervention in patients with NAFLD Dominic Crocombe Received Received
  P01-003 Sodium-glucose cotransporter 2 inhibitor versus sulfonylurea in patients with type 2 diabetes and nonalcoholic fatty liver disease Yumie TAKESHITA Received Received
  P04-003 Effects of coping, quality of life and liver fibrosis on self-efficacy of patients with non-alcoholic fatty liver disease Jesús Funuyet-Salas Received Received
  P02-003 Prediction of fibrosis progression and clinical outcomes with non-invasive tests in 10 years follow up of patients with nonalcoholic steatohepatitis Claudia Oliveira Received Received
  P05-003 Advanced fibrosis in nonalcoholic fatty liver disease is independently associated with reduced renal function Gres Karim Received Received
  P06-003 A co-micronized formulation of palmitoylethanolamide and phenolic compounds from olive leaves lessens hepatic dysmetabolic state in high-fat diet-induced obese mice Stefania Melini Received Received
  P03-003 Fully connected neural network-based serum surface-enhanced Raman spectroscopy accurately identify nonalcoholic steatohepatitis Feng Gao Received Received
  P04-004 Intercellular adhesion molecule-1 is involved in western diet-induced liver damage and metabolic regulation in mice Laura Gebert Received Received
  P02-004 The HDL proteome serves as a mirror for liver dysmetabolism and can delineate healthy from unhealthy obesity Fiona McGillicuddy Received Received
  P01-004 Effects of high fat diet on development of NASH in the NIF mouse model Sofia Mayans Received Received
  P06-004 Insulin resistance in obese children with non-alcoholic fatty liver fibrosis Natalia Zavhorodnia Received Received
  P07-004 NASH PASS: a registry to inform study design and accelerate patient enrollment Alejandra Macias Pulido Received Received
  P03-004 Estrogen-related receptor alpha regulates ribosomal stalk protein RPLP1-dependent translation of lysosome and autophagy proteins in fasting and non-alcoholic steatohepatitis (NASH). Brijesh Kumar Singh Received Received
  P05-004 Exploring the impact of the genetic PNPLA3 I148M variant on primary human hepatic stellate cells by using healthy and diseased 3D extracellular matrix scaffolds Elisabetta Caon Received Received
  P04-005 Carvedilol modifies metabolomics of bile acids in mice: effect of nonalcoholic steatohepatitis Stanislav Micuda Received Received
  P01-005 Hydroxysteroid 17-beta sterol dehydrogenase 13 knockdown improves liver steatosis in mice fed a high-fed diet Shehroz Mahmood Received Received
  P06-005 Prospective relationship between PCOS plus NAFLD at age 17 years, and insulin resistance and atherogenic dyslipidaemia 10 years later in a longitudinal cohort study Oyekoya Ayonrinde Received Received
  P02-005 Characterization of cognitive function in patients with non-alcoholic fatty liver disease and association with the risk of progressive non-alcoholic steatohepatitis Aurora Nicolosi Received Received
  P03-005 Burden of hepatocellular cancer in patients with type-2 diabetes mellitus: a 2010-2020 national cohort study Juan Pablo Scarano Pereira Received Received
  P05-005 Community NAFLD screening programme in patients with T2DM indicates high burden of undiagnosed liver disease Emma McCormick Received Received
  P03-006 Echocardiography-based markers of subclinical cardiac dysfunction in individuals with non-alcoholic fatty liver disease and preserved ejection fraction Angelo Armandi Received Received
  P01-006 Contribution of multiple hit to NAFLD pathology differ in obese and non obese population Souveek Mitra Received Received
  P05-006 Prevalence and clinical characteristics of nonalcoholic fatty liver disease in morbidly obese patients before and after bariatric surgery Sangmi Jang Received Received
  P04-006 Dysregulation of the urea cycle enzymes determines a more severe NAFLD phenotype in diamond mice Rocío Gallego-Durán Received Received
  P07-006 miR-423-5p is associated with hepatic injury in a non-alcoholic fatty liver disease (NAFLD) preclinical model Rocío Montero Received Received
  P02-006 Hepatoprotective effects of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC progression Andreas Nygaard Madsen Received Received
  P06-006 Presumed NASH fibrosis as per noninvasive screening blood marker LIVERFASt-GP is predictive for Covid-19 short-term severe outcome Mona munteanu Received Received
  P06-007 Novel MAFLD classification: a more realistic concept of fatty liver disease Juliana Serrazina Received Received
  P04-007 Impact of genes related to metabolic MAFLD in response to hypocaloric dietary intervention: nutrigenomic analysis Sheila Gato Zambrano Received Received
  P01-007 Association between advanced stage of liver fibrosis in patients with metabolic fatty liver disease and intestinal permeability Tatyana Krolevets Received Received
  P07-007 A specific lipidomic fingerprint is associated with the development of nalfd-associated hcc in an animal model Jian Huang Received Received
  P02-007 Impact of dietary intake on the risk for significant fibrosis in patients with MAFLD Nuria Pérez Diaz del Campo Received Received
  P05-007 Target metabolomics reveals the inhibition of the bile acid alternative pathway promotes the development of non-alcoholic steatohepatitis in mice Dapeng Li Received Received
  P03-008 Pregnancy as a unique opportunity to identify NAFLD in women: a prospective assessment Tatyana Kushner Received Received
  P01-008 LIVRQNac increases fatty acid oxidation in a primary human hepatocyte model of non-alcoholic steatohepatitis Matthew Russell Received Received
  P07-008 Quantification of hepatic steatosis with a novel attenuation imaging ultrasound technique (QAI): preliminary findings on reproducibility and diagnostic accuracy Mattia Paratore Received Received
  P04-008 Functionalizing novel cancer related genes in liver disease and liver regeneration Nooshin Nourbakhsh Received Received
  P05-008 Immune modulation by RIPK3 in NAFLD progression towards hepatocellular carcinoma André F. L. Cardador Received Received
  P06-008 Utilization of gluconeogenic glucose-6-phosphate via pentose phosphate pathway is increased in mice fed a high fat/high sugar diet compared to a high sugar diet alone Getachew Debas Belew Received Received
  P02-008 Therapeutic target identification by genome-wide RNAi screening in non-alcoholic fatty liver (NAFLD) Amanpreet Kaur Received Received
  P06-009 A monoclonal antibody targeting non-junctional Claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity Antonio Saviano Received Received
  P07-009 Role of TGR5 in fat-to-liver communication through extracellular vesicles in the context of NAFLD André L. Simão Received Received
  P04-009 Lipid profiling of extracellular vesicles and plasma in people with non-alcoholic fatty liver disease Dan Wang Received Received
  P05-009 Fluorescent advanced glycation end products levels in the brazilian longitudinal study of adult health (ELSA-Brasil): a potential biomarker for risk stratification of non-alcoholic fatty liver disease-associated steatosis Evelyn Pereira Received Received
  P01-009 Predictors of steatohepatitis in hypertensive nonalcoholic fatty liver disease patients Iryna Tverezovska Received Received
  P02-009 Identifying novel epigenetic regulators of non-alcoholic fatty liver disease using in vivo RNAi screen Chee Chong Jonathan Lek Received Received
  P03-009 Oxygen-nutrient mismatch correction by obeticholic acid suggests mechanism of action in NASH Gerond Lake-Bakaar Received Received
  P01-010 Relationship between endothelial dysfunction and non-alcoholic fatty liver disease Kateryna Pivtorak Received Received
  P04-010 Non-invasive tests for non-alcoholic fatty liver disease (NAFLD) in a multi-ethnic population. The Helius study Anne-Marieke Van Dijk Received Received
  P06-010 A translational rat model to study metabolic associated fatty liver disease with fibrosis and portal hypertension Juan Manuel Pericàs Received Received
  P02-010 Interactive role of non-invasive assessment of insulin resistence and liver fibrosis in the prediction of cardiovascular events in patients with MAFLD Diego Martinez-Urbistondo Received Received
  P05-010 Multiparametric ultrasound evaluation of the liver: whom would mostly benefit? Iulia Minciuna Received Received
  P07-010 Double-blinded randomized controlled trial assessing the effect of consecutive fecal microbiota transplantation (FMT) on hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD) Koen van Son Received Received
  P04-011 Improving diagnostic performance of liver fibrosis, NASH and NAFLD activity score (NAS) with 3D vector magnetic resonance elastography (MRE) Nana Owusu Received Received
  P02-011 Yeast -glucan improves insulin sensitivity and hepatic lipid metabolism in mice humanized with obese type 2 diabetic gut microbiota Kathleen Mitchelson Received Received
  P07-011 Telmisartan improves hepatic mitochondrial energy metabolism in mouse nutritional model of nonalcoholic steatohepatitis Pavla Stankova Received Received
  P03-011 NAFLD-related liver fibrosis is associated with impaired bone mineralization and degraded micro-architecture in obesity Ilaria Barchetta Received Received
  P06-011 Glutaminolysis and steatosis to steatohepatitis transition: role of glutaminase Rocío Gallego-Durán Received Received
  P05-011 A global survey of health care professionals awareness of nonalcoholic fatty liver disease Stan Driessen Received Received
  P01-011 Liver stiffness is associated with excess mortality in the general population driven by heart failure: The Rotterdam study Laurens Van Kleef Received Received
  P02-012 Impact of renaming NAFLD to MAFLD in a single italian center Valentina Cossiga Received Received
  P03-012 Diagnosis of NAFLD with and without fibrosis using a lower ALT reference range in the iLFT system Christopher Byrne Received Received
  P01-012 The role of Gremlin-1 in pathogenesis and treatment in rodent and human NASH Paul Horn Received Received
  P07-012 Predictors of liver stiffness changes in a consecutive cohort of patients with NAFLD and longitudinal follow up Mirko Zoncapè Received Received
  P06-012 The use of spleen stiffness measurement as non-invasive tool to identify histological cirrhosis in individuals with non-alcoholic fatty liver disease Angelo Armandi Received Received
  P05-012 Quantitification of hepatic steatosis in patient with non-alcoholic fatty liver disease : comparison of sound speed, attenuation coefficient and continuous CAP measurements with MR-PDFF Rémi COLLIN Received Received
  P04-012 Pegozafermin improved liver histology, liver-related non-invasive tests (NITS) and metabolic profiles in an open-label cohort of a phase 1b/2a study in subjects with non-alcoholic steatohepatitis Cindy Hartsfield Received Received
  P04-013 NAFLD is associated with significantly higher risk of cardiovascular outcomes in the absence of fibrosis - a prospective UK Biobank analysis in 33,616 individuals Anneli Andersson Received Received
  P03-013 The SEMA7A_R148W mutation promotes lipid accumulation and NAFLD progression by increasing its localization on hepatocyte surface Jin Chai Received Received
  P01-013 Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of NASH Susanne Pors Received Received
  P06-013 Free light chains: a new potential biomarker for disease stratification in non-alcoholic steatohepatitis Francesca DAmbrosio Received Received
  P07-013 Circulating Interleukin-32 levels are associated with arterial hypertension in individuals at risk of NAFLD Melissa Tomasi Received Received
  P02-013 Prevalence and risk factors for non-alcoholic fatty liver disease in patients with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-regression Clara Sabiote Cartes Received Received
  P05-013 Clinical variables influence performance of non-invasive tests for non-alcoholic fatty liver disease Anne-Marieke Van Dijk Received Received
  P03-014 Branched-chain amino acid catabolism and hepatic stellate cell activation Rory Turner Received Received
  P05-014 Modelling clinical effect of patatin-like phospholipase domain containing 3 mutation in hepatocytes on severity of disease progression in 3D human NASH model Thomas Hofstetter Received Received
  P06-014 Micro-lAIver: artificial intelligence-powered drug screening platform for 3D-bioprinted human liver microspheres Francesco De Chiara Received Received
  P02-014 Non-alcoholic fatty liver disease related knowledge among egyptians: an exploratory cross-sectional study Mona Hegazy Received Received
  P04-014 Decreases in liver cT1 accurately reflect therapy-induced histological improvements in NASH: a multi-centre pooled analysis Cayden Beyer Received Received
  P01-014 Sex-specific hepatoprotective effects of long-term semaglutide treatment in GAN diet-induced obese and biopsy-confirmed mouse model of NASH Kristoffer Voldum-Clausen Received Received
  P07-014 Phosphatidylcholines (36:1) and (36:3) are increased in postmenopausal women with NAFLD. Dan Wang Received Received
  P07-015 Multiparametric liver ultrasound assessment for stratification of non-alcoholic fatty liver disease (NAFLD) severity: a possible role for viscosity Antonio Liguori Received Received
  P04-015 MRI assessment (cT1) with LiverMultiScan following VCTE improves the diagnostic yield for high-risk NASH Cayden Beyer Received Received
  P05-015 Single-nucleus ATAC-seq elucidates major modules of gene regulation in the development of non-alcoholic fatty liver disease Fumihiko Takeuchi Received Received
  P01-015 Meat consumption and PNPLA3 polymorphism are associated with fatty liver in a multi-center cross-sectional study Claudia Oliveira Received Received
  P02-015 Impact of sexual dimorphism and aging on NAFLD severity and advanced fibrosis Mona Hegazy Received Received
  P03-016 Secretome analysis of non-diabetic patients with non-alcoholic fatty liver disease identifies glucose-dependent insulinotropic peptide (GIP) and interferon gamma-induced protein 10 (IP-10) as biomarkers of at risk non-alcoholic steatohepatitis Gian Paolo Caviglia Received Received
  P05-016 Association of thyroid dysfunction and raised sgpt values in children with obesity and severe obesity in greece: results of a tertiary paediatric hospital experience Anastasia Konidari Received Received
  P04-016 Prevalence of subclinical cardiovascular disease in patients with non-alcoholic fatty liver disease. Analysis of the Paracelsus 10.000 cohort study Florian Koutny Received Received
  P07-016 Calorie restriction combined with metformin promote the remission of NAFLD Elisabet Rodríguez-Tomàs Received Received
  P01-016 Primary data analyses of MAESTRO-NAFLD-1: a 52-week randomized double-blind placebo-controlled Phase 3 trial of resmetirom in patients with nonalcoholic fatty liver disease Stephen Harrison Received Received
  P06-016 The controlled attenuation parameter has limited value in assessing the degree of steatosis in different stages of compensated chronic liver disease Madalina Gabriela Taru Received Received
  P02-016 Metabolic associated fatty liver disease: association between the three different criteria definition and hepatic and cardiovascular disease Rosa Lombardi Received Received
  P02-017 Type 2 diabetes and religious fasting: effects on metabolism and liver steatosis Paul Manka Received Received
  P05-017 3D human NASH model as a screening-based discovery approach for ing and prioritizing drug candidates Simon Strbel Received Received
  P07-017 NAFLD identification gap in italian primary care is due to a lack of proper ICD9 coding for disease Marianxhela Dajko Received Received
  P06-017 Cost-effectiveness of magnetic resonance elastography for non-alcoholic steatohepatitis fibrosis in the United Kingdom Michael Kalutkiewicz Received Received
  P01-017 Non alcoholic fatty liver disease is associated to post-acute COVID syndrome Fabrizio Mancuso Received Received
  P04-017 Effect of smartphone-assisted lifestyle modification intervention in MAFLD patients: a randomized controlled trial Suraphon Assawasuwannakit Received Received
  P03-017 A calorie-unrestricted low carbohydrate high fat diet improves nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in type 2 diabetes: a six-month randomised controlled trial Camilla Dalby Hansen Received Received
  P02-018 The paraoxonase gene family in the etiology and progression of obesity and associated liver disease: a genetic case-control study Evelien Van Dijck Received Received
  P03-018 Prognostic value of liver stiffness and FIB-4 score in individuals with cirrhosis due to non-alcoholic fatty liver disease without previous liver decompensation Amina Abdulle Received Received
  P05-018 Multiplex immunostaining identifies novel immune cell markers for non-alcoholic fatty liver disease and primary sclerosing cholangitis Marlene Kohlhepp Received Received
  P04-018 Proteomics and spatial transcriptomics show that ADAMTSL2 is a promising biomarker in NAFLD with significant fibrosis Elisabeth Galsgaard Received Received
  P07-018 Liraglutide ameliorates steatotic changes in a cell culture model of tamoxifen-induced steatosis by downregulation of lipogenic ACSL1 and SREBP-1c signaling pathways Tea Omanovic Kolaric Received Received
  P06-018 foz/foz mice with non-alcoholic steatohepatitis feature pathological cardiac hypertrophy Sebastian Bott Received Received
  P01-018 Clinical characteristics of non-alcoholic fatty liver disease in pregnant women with varying degrees of obesity Lina Bahniy Received Received
  P02-019 Missed opportunities to co-diagnose alcohol-related liver disease in patients diagnosed with non-alcoholic fatty liver disease Tobias Maharaj Received Received
  P07-019 Aging contributes to the loss of glycerophospholid in adipocytes in NAFLD mice model Gerard Baiges Received Received
  P05-019 Tackling stages of fibrosis in metabolic-associated liver diseases with transcriptome profiles Eva Kocar Received Received
  P01-019 Validation of elastography criteria and cACLD risk model for diagnosis of compensated advanced Chronic liver disease (cACLD) in a UK cohort of NAFLD patients Antonio Liguori Received Received
  P04-019 Long term safety and efficacy of saroglitazar in NAFLD/NASH population: a prospective, single arm, real world study Sujit Chaudhuri Received Received
  P03-019 Impact of intermittent fasting on anthropometric and clinical outcomes in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis Marcia Lange Received Received
  P04-020 Dysregulated wound healing contributes to the progression of post-transplant non-alcoholic steatohepatitis Khairunnadiya (Nadia) Prayitno Received Received
  P02-020 NAFLD and liver stiffness predict clinical events and chronic kidney disease in patients with type-2 diabetes Jesús Rivera Received Received
  P07-020 Fatty liver disease in ALPHA-1 deficiency patients Hassaan Yousuf Received Received
  P03-020 Hepatocellular cancer surveillance in cirrhotic patients with fatty liver disease Chloe Attree Received Received
  P01-020 Antagonizing sodium taurocholate co-transporting polypeptide (NTCP) on NK cells from NALFD patients elevate their activity and mediate activated hepatic stellate cells killing Ahmed Salhab Received Received
  P05-020 Performance of FIB-4 compared to vibration controlled transient elastography in people with type 1 and type 2 diabetes Jonathan Mertens Received Received
  P06-020 Predictive survival-time modelling of non-alcoholic steatohepatitis (NASH) fast progressors using real-world evidence Nils Svangrd Received Received
  P07-021 Molecular mechanisms involved in metabolic dysfunction- associated fatty liver disease in cholecystectomized patients Nahum Méndez-Sánchez Received Received
  P01-021 Tissue resident NK NTCP- transplanted to immunosuppressed mice exhibiting liver fibrosis and fed with high fat diet (HFD) alleviate intestinal fibrosis and lipid profile Johnny Amer Received Received
  P06-021 Comparison of severity of liver damage, metabolic alterations and cardiovascular damage in patients with NAFLD attending the hepatology clinic over the last three decades Rosa Lombardi Received Received
  P03-021 Beta 7 integrin-mediated intestinal migration of pro-inflammatory monocytes contributes to western-style diet-induced obesity and non-alcoholic fatty liver disease in mice Sreepradha Eswaran Received Received
  P04-021 Expression dynamics of genes involved in lipid, glucose and xenobiotic metabolism after exposure to nuclear receptor ligands in 3D primary human hepatocyte spheroids Petr Pavek Received Received
  P05-021 Fatty hepatocytes induce skeletal muscle atrophy in vitro: a new three-dimensional platform to study the protective effect of albumin in non-alcoholic fatty liver disease Ainhoa Ferret Miñana Received Received
  P02-021 Investigation of the plasma proteome to identify drug targets for non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease Jun Liu Received Received
  P06-022 The impact of metabolic comorbidities and alcohol consumption on FIB-4 and NFS performance in MAFLD: a multicentric preliminary data Annalisa Cespiati Received Received
  P07-022 Promising ultrasound tools in the management of patients with NAFLD Isabel Garrido Received Received
  P01-022 MRI in NAFLD: calculation of liver fat mass and investigation of its correlation with liver volume and steatosis grade PANAGIOTIS KOUSSIS Received Received
  P05-022 Sex-related differences of hepatic lipid metabolism and mitochondrial function in epileptic WAG/Rij rats: effect of early lipopolysaccharide challenge Claudio Pirozzi Received Received
  P03-022 Comparison of metabolic alterations, hepatic and cardiovascular damage between HIV patients with steatosis and primary NAFLD: role of visceral adiposity Felice Cinque Received Received
  P04-022 Administrative coding for non-alcoholic fatty liver disease is accurate in swedish patients Hanne strm Received Received
  P02-022 Prevalence and risk factors of NAFLD fibrosis amongst penitentiary population in Catalonia. Preliminary results from the PRISONAFLD study. Laura Cecconi Received Received
  P01-023 The crosstalk of liver, muscle and adipose tissue transcriptomics upon exercise in patients with non-alcoholic fatty liver disease Veera Houttu Received Received
  P07-023 Development of fatty liver disease in the portuguese population: can we predict it? Juliana Serrazina Received Received
  P06-023 Prevalence of non-alcoholic fatty liver disease (NAFLD) in middle-aged men and women with overweight and normal liver enzymes, and diagnostic accuracy of non-invasive proxies Koen Van Son Received Received
  P05-023 Anaerobutyricum soehngenii as a next generation therapeutic microbe in a mouse model of non-alcoholic fatty liver disease Anne Linde Mak Received Received
  P03-023 Obeticholic acid modulates DDAH-ADMA-eNOS axis and attenuates portal pressure in an experimental non-alcoholic fatty liver disease Balasubramaniyan Vairappan Received Received
  P04-023 Growth and development of infants born to mothers with nonalcoholic fatty liver disease in pregnancy: a longitudinal study Aliza Gross Received Received
  P02-023 Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease Jian-Hong Zhong Received Received
  P07-024 Performance of fatty liver index in the prediction of advanced chronic liver disease in nonalcoholic fatty liver disease Nouha Trad Received Received
  P03-024 Steroidomic profile is associated with adipose tissue insulin resistance and severe liver fibrosis in non-diabetic patients with non-alcoholic fatty liver disease Chiara Rosso Received Received
  P05-024 VEGF and TGF-1 in children with non-alcoholic fatty liver fibrosis Natalia Zavhorodnia Received Received
  P06-024 Anti-pd-1 treatment affects lipidomic profile in an animal model of NAFLD-HCC Jian Huang Received Received
  P04-024 The prevalence and the assessment of significant and advanced fibrosis of the liver by non-invasive tests in patients with type 2 diabetes mellitus Marie Coessens Received Received
  P02-024 Boosting drug development in NASH through integrated research platforms: proposal of a master protocol for a NASH platform trial Juan Manuel Pericàs Received Received
  P04-025 A screening strategy of non-alcoholic fatty liver disease in endocrine outpatients using the fibrosis-4 score. María Sanz de Pedro Received Received
  P01-025 Effect of peroxisome proliferator-activated receptor-alpha/gamma agonism on fibrosis-4 index in type 2 diabetes mellitus patients with elevated cardiovascular risk profile by sex, age, regional and ethnical differences Vivian de Jong Received Received
  P06-025 Patients with compensated cirrhosis due to NASH show decreased plasma levels of sphingolipids and MCP-1 and increased leptin Antonio Liguori Received Received
  P05-025 Urinary lithogenic profile in patients with non-alcoholic fatty liver disease (NAFLD) Antonio Liguori Received Received
  P02-025 A higher fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with nonalcoholic steatohepatitis Stephen Dodge Received Received
  P07-025 Hepatic senescence is associated with clinical progression of NAFLD/NASH: role of BMP4 and its antagonist Gremlin1 Ritesh Kumar Baboota Received Received
  P03-025 Late chronotype is associated with significant liver fibrosis in patients with non-alcoholic fatty liver disease Gabriele Castelnuovo Received Received
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 15/09/2022 TO 15/09/2023
Featured Poster
Vote poster
Poster Discussion

Logo Draft
Logo Cert